NCT02599129View on ClinicalTrials.gov

A Study of Secukinumab for the Treatment of Alopecia Areata

PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Alopecia Areata
Interventions
DRUG

Secukinumab

subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.

DRUG

Placebo

subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER